Literature DB >> 3758654

Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans.

H Vilhardt, S Lundin.   

Abstract

DDAVP was administered intranasally (20 micrograms) and perorally (100 and 200 micrograms) to 6 hydrated volunteers. Urine was collected and blood was sampled at intervals for the following 6 hr. In all experiments DDAVP induced a marked and long lasting antidiuretic response. Radioimmunoassay of DDAVP in blood samples made it possible to calculate bioavailability of DDAVP after the two forms of administration. Following intranasal application 11.3% of the dose appeared in the blood and the figures for oral administration was 0.7-1.0%. Based on analysis of the amount of DDAVP excreted in the urine the urinary clearance rate was estimated to be 0.10 ml/min/kg body wt.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3758654     DOI: 10.1016/0306-3623(86)90198-9

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  13 in total

1.  Indirect-response modeling of desmopressin at different levels of hydration.

Authors:  T Callréus; J Odeberg; S Lundin; P Höglund
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

2.  Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years.

Authors:  Asa Rembratt; Charlotte Graugaard-Jensen; Thomas Senderovitz; Jens Peter Norgaard; Jens Christian Djurhuus
Journal:  Eur J Clin Pharmacol       Date:  2004-06-09       Impact factor: 2.953

3.  Gastrointestinal absorption and biological activities of serine and cysteine proteases of animal and plant origin: review on absorption of serine and cysteine proteases.

Authors:  Gerhard Lorkowski
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-02-28

Review 4.  Desmopressin: in adults with nocturia.

Authors:  Risto S Cvetković; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Differences in transport rate of oxytocin and vasopressin analogues across proximal and distal isolated segments of the small intestine of the rat.

Authors:  S Lundin; N Pantzar; A Broeders; M Ohlin; B R Weström
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

6.  Clinical study shows improved absorption of desmopressin with novel formulation.

Authors:  Nelly Fransén; Susanne Bredenberg; Erik Björk
Journal:  Pharm Res       Date:  2009-03-19       Impact factor: 4.200

7.  The behaviorally active peptide ACTH 4-10: measurement in plasma and pharmacokinetics in man.

Authors:  U Bickel; J Born; H L Fehm; M Distler; K H Voigt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man.

Authors:  L d'Agay-Abensour; A Fjellestad-Paulsen; P Höglund; Y Ngô; O Paulsen; J C Rambaud
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Improved oral delivery of desmopressin via a novel vehicle: mucoadhesive submicron emulsion.

Authors:  E Ilan; S Amselem; M Weisspapir; J Schwarz; A Yogev; E Zawoznik; D Friedman
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

10.  Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (dDAVP).

Authors:  A H Kahns; A Buur; H Bundgaard
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.